Retrospective Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Nov 7, 2017; 23(41): 7397-7406
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7397
Table 4 Baseline disease characteristics, endoscopic balloon dilation procedure, need for further dilations, escalation of medical therapy and need for surgery between asymptomatic and symptomatic cohorts n (%)
CharacteristicAsymptomatic strictures1 (n = 53)Symptomatic strictures1 (n = 25)P value
Female/male (n)25/2816/90.165
Disease duration in years (median; min-max)17.9 (2.9-45.3)19.9 (5.3-52.1)0.955
Follow-up since 1st dilation in years (median; min-max)3.1 (1.3-6.8)3.9 (2.1-6.7)0.068
Time between 1st and 2nd dilation in days (median; min-max)668 (157-2074)877 (152-2242)0.790
Age at index colonoscopy (mean ± SD)41.7 ± 13.843 ± 9.30.425
Montreal classification
Age at diagnosis0.998
A17 (14)3 (13.6)
A236 (72)16 (72.7)
A37 (14)3 (13.6)
Disease location0.319
L122 (44)9 (40.9)
L25 (10)-
L321 (42)9 (40.9)
L1-41 (2)4 (18.2)
L3-41 (2)-
Behavior0.833
B14 (8)1 (4.5)
B228 (56)12 (54.5)
B318 (36)9 (40.9)
Perianal disease15 (30)6 (27.3)0.815
Smoking habits0.761
Non-smoker24 (52.2)8 (42.1)
Ex-smoker8 (17.4)4 (21.2)
Current smoker14 (30.4)7 (36.8)
Previous surgery (ileocecal resection/right hemicolectomy)27 (50.9)15 (60)0.454
Medication at index colonoscopy
Thiopurines33 (62.3)13 (52)0.390
Anti-TNFα21 (39.6)14 (56)0.175
Combo13 (24.5)9 (36)0.293
C-reactive protein6.2 (0.2-35.5)3.2 (0.3-19.4)0.351
Calprotectin107 (18.2-837)340 (5.9-1356)0.449
Lactoferrin7.1 (1.1-102.6)37.6 (4.0-204)0.071
Therapeutic success52 (98.1)25 (100%)0.377
Balloon diameter (median; min - max)18 (10-18)18 (13.5-18)0.201
Adverse events0 (0)1 (4)0.129
Need to repeat dilation27 (50.9)15 (60)0.454
Number of dilations (median; min - max)2 (1-5)2 (1-5)0.463
Escalation of medical therapy after dilation13 (27.7)8 (34.8)0.541
Need for surgery after dilation2 (4)1 (4.2)0.973